Kalliopi P Siziopikou1. 1. Breast Pathology Service, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. p-siziopikou@northwestern.edu
Abstract
CONTEXT: In situ carcinomas of the breast constitute 15% to 30% of all newly diagnosed breast cancer cases; 80% of these in situ lesions belong to the ductal carcinoma in situ (DCIS) category. Similar to invasive breast carcinomas, DCIS is not a single disease but rather many distinct diseases with different histopathologic and molecular characteristics, a propensity to progress to invasive disease, and differential response to treatment. OBJECTIVE: To review the classic pathologic parameters of clinical significance and the differential diagnosis of the DCIS lesions, present our new understanding of the importance of biomarkers, and discuss innovative approaches for targeted therapy in DCIS. DATA SOURCES: Extensive review of the relevant peer-reviewed literature. CONCLUSIONS: In DCIS, improved understanding of the underlying biologic pathways of tumor progression is expected to lead to more accurate classification and innovative targeted treatment approaches for the management of these lesions.
CONTEXT: In situ carcinomas of the breast constitute 15% to 30% of all newly diagnosed breast cancer cases; 80% of these in situ lesions belong to the ductal carcinoma in situ (DCIS) category. Similar to invasive breast carcinomas, DCIS is not a single disease but rather many distinct diseases with different histopathologic and molecular characteristics, a propensity to progress to invasive disease, and differential response to treatment. OBJECTIVE: To review the classic pathologic parameters of clinical significance and the differential diagnosis of the DCIS lesions, present our new understanding of the importance of biomarkers, and discuss innovative approaches for targeted therapy in DCIS. DATA SOURCES: Extensive review of the relevant peer-reviewed literature. CONCLUSIONS: In DCIS, improved understanding of the underlying biologic pathways of tumor progression is expected to lead to more accurate classification and innovative targeted treatment approaches for the management of these lesions.
Authors: Serdar Altinay; Laurent Arnould; Noella Bletard; Cecile Colpaert; Franceska Dedeurwaerdere; Benjamin Dessauvagie; Valérie Duwel; Giuseppe Floris; Stephen Fox; Clara Gerosa; Shabnam Jaffer; Eline Kurpershoek; Magali Lacroix-Triki; Andoni Laka; Kathleen Lambein; Gaëtan Marie MacGrogan; Caterina Marchió; Dolores Martin Martinez; Sharon Nofech-Mozes; Dieter Peeters; Alberto Ravarino; Emily Reisenbichler; Erika Resetkova; Souzan Sanati; Anne-Marie Schelfhout; Vera Schelfhout; Abeer M Shaaban; Renata Sinke; Claudia Maria Stanciu-Pop; Claudia Stobbe; Carolien H M van Deurzen; Koen Van de Vijver; Anne-Sophie Van Rompuy; Stephanie Verschuere; Anne Vincent-Salomon; Hannah Wen; Hélène Dano; Caroline Bouzin; Christine Galant; Mieke R Van Bockstal Journal: Mod Pathol Date: 2019-09-18 Impact factor: 7.842
Authors: Michael J Campbell; Frederick Baehner; Tess O'Meara; Ekene Ojukwu; Booyeon Han; Rita Mukhtar; Vickram Tandon; Max Endicott; Zelos Zhu; Jasmine Wong; Gregor Krings; Alfred Au; Joe W Gray; Laura Esserman Journal: Breast Cancer Res Treat Date: 2016-10-26 Impact factor: 4.872
Authors: Gary D Lewis; Waqar Haque; Andrew Farach; Sandra S Hatch; E Brian Butler; Polly A Niravath; Mary R Schwartz; Elizabeth Bonefas; Bin S Teh Journal: Rep Pract Oncol Radiother Date: 2021-04-14